MedDataX Logo

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USA

NCT00958126 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1313

Last updated 2017-11-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults

Conditions

  • Influenza

Interventions

BIOLOGICAL

CSL425

CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.

BIOLOGICAL

CSL425

CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).

BIOLOGICAL

Placebo

Vaccine diluent, thimerosal 0.01% (weight/volume).

Sponsors & Collaborators

  • Seqirus

    lead INDUSTRY

Principal Investigators

  • Director, Vaccines Clinical Development · Seqirus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-11-30
Completion
2010-04-30

Countries

  • United States

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958126 on ClinicalTrials.gov